Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.92 | 0.28 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avai Bio, Inc., formerly Avant Technologies, Inc., is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing cell-based therapies. The Company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an a-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. It has secured Joint Venture and Licensing Agreements to develop both cell lines. Its diabetes program is focused on developing an insulin-producing cell line, then encapsulating those cells inside using SGAustria's Cell-in-a-Box technology to create a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes. The Company is partnering with biotech firms, universities, scientists, and clinicians to uncover solutions for diverse healthcare challenges.
Directors
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- November 6th, 2017
- Public Since
- May 2nd, 2019
- No. of Shareholders
- 110
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 153,916,565
- Address
- c/o Eastbiz.com, Inc, 5348 Vegas Drive, LAS VEGAS, 89108
- Web
- https://avaibio.com
- Phone
- +1 null8665330065
- Auditors
- DylanFloyd Accounting & Consulting
Latest News for AVAI
Upcoming Events for AVAI
Similar to AVAI
1606
Pink Sheets on Nasdaq
Ablaze Technologies
Pink Sheets on Nasdaq
Acasia Technology
Pink Sheets on Nasdaq
Accelerated Technologies Holding
Pink Sheets on Nasdaq
Affluence
Pink Sheets on Nasdaq
FAQ
As of Today at 09:27 UTC, shares in Avai Bio are trading at $0.10. This share price information is delayed by 15 minutes.
Shares in Avai Bio last closed at $0.10 and the price had moved by -74.92% over the past 365 days. In terms of relative price strength the Avai Bio share price has underperformed the S&P500 Index by -77.24% over the past year.
There is no consensus recommendation for this security.
Find out moreAvai Bio does not currently pay a dividend.
Avai Bio does not currently pay a dividend.
Avai Bio does not currently pay a dividend.
To buy shares in Avai Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.10, shares in Avai Bio had a market capitalisation of $14.81m.
Here are the trading details for Avai Bio:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AVAI
Based on an overall assessment of its quality, value and momentum Avai Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avai Bio. Over the past six months, its share price has underperformed the S&P500 Index by -67.37%.
As of the last closing price of $0.10, shares in Avai Bio were trading -58.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Avai Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Avai Bio's management team is headed by:
- Natalija Tunevic - SEC
- Vitalis Racius - CFO
- Ivan Lunegov - PRE
- Chris Winter - CEO